Revolutionizing Atopic Dermatitis (RAD)

home / conference / revolutionizingatopicdermatitis

RAD is where your goal to improve patients’ lives converges with meaningful discussions and groundbreaking concepts in atopic dermatitis. At this dynamic gathering, evidence drives conversations and strategies that matter are conceived, giving you an unparalleled platform to expand your skills. This year, we’re turning up the energy in Nashville. Get ready to experience Nashville’s vibrant culture and iconic music scene, right here at RAD!

Conference Highlights

Expert Interviews

Featured

RAD 2025: What You May Have Missed

Sydney Jennings

Expanding Access to Atopic Dermatitis Treatments for Children: A Conversation with Elizabeth Swanson, MD

Sydney Jennings

Elizabeth Swanson, MD, FAAD

Q&A: JAK Inhibitor Safety in Context and the Rich Atopic Dermatitis Pipeline, with Leon Kircik, MD

Leon Kircik, MD

Why the OX-40/OX-40L Pathway Matters in Atopic Dermatitis—and What’s Next: A Q&A with Johann Gudjonsson, MD, PhD

Sydney Jennings

Johann Gudjonsson, MD, PhD

A Close Look at Flexible Dosing Strategies for Atopic Dermatitis in Adults with Raj Chovatiya, MD, PhD, MSCI

Raj Chovatiya, MD, PhD, MSCI

Pediatric Atopic Dermatitis: Navigating Patient, Provider, Caregiver Connection with Peter Lio, MD

Peter A Lio, MD

Sydney Jennings

Lebrikizumab Demonstrates Efficacy, Safety in Patients With Skin of Color With AD

Sydney Jennings

Flexible Dosing in in Atopic Dermatitis Treatment: Notes on Real-World Use with Raj Chovatiya, MD, PhD, MSCI

Raj Chovatiya, MD, PhD, MSCI

Q&A: Cumulative Life Course Impairment of Atopic Dermatitis with Mona Shahriari, MD

Mona Shahriari, MD

Chronic Hand Eczema: Clinical Insights and Future Directions from RAD 2025

Sydney Jennings

Upadacitinib Shows Real-World Efficacy in Bio-Naïve, Bio-Experienced Adults with Atopic Dermatitis in New Study

Sydney Jennings

Q&A: Managing Chronic Itch With Renowned Investigator Gil Yosipovitch, MD

Gil Yosipovitch, MD

Beyond the Rash: Collaborative Insights on Pediatric Atopic Dermatitis

Sydney Jennings

Lisa Swanson, MD

Persistent Underutilization of Systemic Therapy for Atopic Dermatitis Highlights Gap Between Need and Care

Dupilumab Monotherapy Improves AD Severity and Pigmentation in People With Skin of Color

Sydney Jennings

Long-Term Data on Nemolizumab Demonstrate Safety, Sustained Symptom Improvement in Patients With Atopic Dermatitis up to 2 Years

Mona Shahriari, MD: Explore the Psychosocial Burden of Atopic Dermatitis with Your Patients—Ask Questions

Mona Shahriari, MD

Ruxolitinib Cream Demonstrates Long-Term Safety and Disease Control in Young Patients With Atopic Dermatitis

Nemolizumab Improves Pruritis, Sleep Within 2 Days When Added to Standard Topical Therapy for Atopic Dermatitis

Dupilumab Sustains Long-Term Reduction of Staphylococcus aureus in Patients with Atopic Dermatitis

Sydney Jennings

INTEGUMENT-OLE: Roflumilast Cream Maintains Long-Term Disease Control in Pediatric and Adolescent Atopic Dermatitis

Sydney Jennings

Lebrikizumab Maintains Deep Response, QoL Through 3 Years in Atopic Dermatitis Extension Study

Sydney Jennings

Roflumilast Cream 0.15% Demonstrates Safety, Tolerability in Individuals With Atopic Dermatitis With Prior Treatment Failures

Real-World Abrocitinib Study Shows Most Patients Maintain Consistent Dosing in Atopic Dermatitis Treatment

Patient Survey Highlights Importance of Itch Relief, Personalized Guidance in Atopic Dermatitis Treatment

Sydney Jennings

Long-Term Roflumilast Data Show Durable Efficacy in Young Children and Adults with Atopic Dermatitis

New Data on Atopic Dermatitis for Frontline Clinicians: RAD 2025 Preview

Sydney Jennings

Immunization in America: Highs and Lows by State

Sydney Jennings

Global Burden of Atopic Dermatitis in Older Adults Underestimated and Expected to Rise Substantially by 2050

Editorial Board

Terms and Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.